<DOC>
	<DOCNO>NCT00925587</DOCNO>
	<brief_summary>The purpose study determine whether monthly ( QM ) dose darbepoetin alfa non-inferior every 2 week ( Q2W ) dose darbepoetin alfa correction anemia patient Chronic Kidney Disease receive dialysis .</brief_summary>
	<brief_title>Evaluation Monthly Darbepoetin Alfa Dosing Correction Anemia Non-dialysis Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>≥ 18 year age Diagnosis chronic kidney disease eGFR 1559 mL/min/1.73 m2 ( MDRD equation ) Two consecutive screen Hb value take least 7 day apart must &lt; 10.0 g/dL TSAT ≥ 15 % Upper low GI bleed within 6 month enrolment ESA use within 12 week enrolment Uncontrolled hypertension Systemic haematologic disorder Prior history within 12 week enrollment event include : Acute myocardial ischemia , unstable angina , myocardial infarction , hospitalization congestive heart failure , stroke transient ischaemic attack , limb ischaemia , deep vein thrombosis , thromboembolism . Grand mal seizure within 6 month prior enrolment Evidence , receive chemotherapy radiation therapy , malignancy within 5 year prior enrolment . Red blood cell transfusion within 12 week prior enrolment Androgen therapy within 8 week prior enrolment Pregnancy breast feeding , inadequate contraception Currently receive immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>CKD</keyword>
	<keyword>Anemia</keyword>
	<keyword>correction</keyword>
	<keyword>darbepoetin alfa</keyword>
</DOC>